3衍生物。一項由1 054例骨質(zhì)疏松癥患者參加的歷時3年的III期臨床數(shù)據(jù)顯示,艾爾骨化醇療效優(yōu)于阿法骨化醇,且安全性與阿法骨化醇相似,具有較好的應(yīng)用前景。;After following alfacalcidol, eldecalcitol (brand name Edirol?), obtained an approval to market in 21th January, 2011 from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patient with osteoporosis, is a novel active vitamin D3 derivative. During three years of the phase III study on 1054 patients suffered from osteoporosis, the three-year incidence of bone fractures were observed and the safety of eldecalcitol used for the treatment of those patients with osteoporosis was compared to that of alfacalcidol. The patients who received eldecalcitol had a significantly lower three-year incidence of new vertebral fractures. Overall, the safety profiles of the two agents are similar, which indicates that eldecalcitol is superior to alfacalcidol and has a better prospect in preventing and treating fractures."/> 3;艾爾骨化醇(eldecalcitol);Edirol;阿法骨化醇;骨質(zhì)疏松;active vitamin D3; eldecalcitol; Edirol; alfacalcidol; osteoporosis"/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2011年第34卷第3期 >2011,34(3):224-229. DOI:10.7501/j.issn.0253-6376.[year].3.[sequence]
上一篇 | 下一篇

骨質(zhì)疏松癥治療藥物——艾爾骨化醇

Advance and prospect of research on un-dried crude drug

發(fā)布日期:
您是第位訪問者
藥物評價研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號:(津)-非經(jīng)營性-2015-0031